Plenary Session
Vinay Prasad, MD MPH
Add to My Podcasts
Episodes
About
Reviews
Promote
4.67 Teclistimab for R/R Multiple Myeloma
37 minutes
Posted Jun 9, 2022 at 10:56 pm.
0:00
37:42
Add to My Queue
Download
MP3
Share
episode
Share at current time
Show notes
The drug has a high response rate and lots of infections, is it active? Yes; Efficacious? ???? I review ASCO2022 updates
Previous
4.66 PD1 Ab for MSI H Stage II/ III Rectal Cancer; A 100% CR rate??
Next
QuANTUM - Quizartinib Front Line - Ethics of Global Trials
← See all 401 episodes of Plenary Session